406PResponse assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: A comparison of RECIST 1.1, RANO and iRANO criteria

ConclusionsWhile the retrospective nature and small sample size for subgroups are major limitations of this study, these data may indicate that the omission of SRT from first-line treatment may compromise outcome. Pseudoprogression is uncommon with immunotherapy alone; pseudoprogression rates were similar after SRT alone or in combination with immunotherapy or other systemic treatment.Legal entity responsible for the studyUniversity Hospital of Zurich.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research